Viiv Healthcare sales and marketing update

ViiV launched HIV drug Tivicay dolutegravir from ViiV in the U.K. In January, the European Commission approved Tivicay to treat HIV infection in combination with other antiretroviral agents in patients at least 12 years old. FDA approved the HIV integrase inhibitor in August, and Health Canada approved the drug in October. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), Pfizer Inc. (NYSE:PFE, New York, N.Y.) and Shionogi & Co. Ltd. (Tokyo:4507, Osaka, Japan) own ViiV (see BioCentury, Jan. 27). ...